跳至主要内容
临床试验/NCT01041924
NCT01041924Unknown2 期

Dynamic Carbon Dioxide Administration for Central Sleep Apnoea in Heart Failure

Imperial College London4 个研究点 分布在 2 个国家目标入组 24 人开始时间: 2010年2月最近更新:
适应症

试验速览

阶段
2 期
入组人数
24
试验地点
4
主要终点
Arousals

研究概览

简要总结

Normally breathing is controlled by a reflex that responds to the levels of carbon dioxide (CO2) in the blood. In heart failure, where the heart muscle is damaged and therefore does not pump as well, this reflex is exaggerated. The result is a vicious circle: blood CO2 levels fluctuate wildly and as a result breathing also fluctuates with patients hyperventilating at times and briefly stopping breathing at others. During sleep this is called central sleep apnoea (CSA).

Patients with CSA wake up throughout the night and whilst some patients are oblivious to this, others are consciously breathless and many patients are tired during the day and feel unable to perform their daily activities.

As part of the body's stress response to the erratic pattern of breathing, both blood pressure and heart rate may rise to a level that is harmful in a failing heart, exacerbating the underlying heart failure. Indeed patients who demonstrate this CSA die sooner than those who have heart failure and stable breathing.

There are no proven specific therapies for CSA that stabilise breathing, improve sleep quality, and prolong life. We have designed a system which delivers very small doses of CO2, when the blood level of CO2 is predicted to be low. During short daytime recordings, using this system, we have demonstrated that it is possible to stabilise the body's CO2 levels.

We aim to test what happens when CO2 is given overnight whilst the patient is sleeping to see whether we can stabilise their breathing over longer durations and whether sleep quality could be improved so that patients are less tired during the day. In addition, we would like to measure whether the stress response is lessened if the breathing is successfully stabilised.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women 18 to 79 years of age who have New York Heart Association (NYHA) functional class I through IV heart failure due to ischemic, hypertensive, or idiopathic dilated cardiomyopathy and whose condition had been stabilized by means of optimal medical therapy for at least one month;
  • An LVEF of less than 40% and central sleep apnea, defined as 15 or more episodes of apnea and hypopnea per hour of sleep, more than 50 percent of which are determined to be central rather than obstructive.

排除标准

  • Pregnancy,
  • Myocardial infarction,
  • Unstable angina or cardiac surgery within the previous three months.

结局指标

主要结局

Arousals

时间窗: over 8 hours

Extent of respiratory instability

时间窗: over 8 hours

次要结局

  • End-tidal CO2(per breath)
  • 24 hour urinary catecholamines(per 24 hours)
  • Mean heart rate(per 1 s)
  • Number of ectopic heart beats(per 8 hours)
  • Mean blood pressure(every 9 hours)
  • Mean Ventilation(every 1 second)

研究者

申办方类型
Other

研究点 (4)

Loading locations...

相似试验